(Q28200350)

2

0 references

K Matsui

3

0 references

S Negoro

4

0 references

N Yamamoto

5

0 references

J E Latz

6

0 references

S Adachi

7

0 references

M Fukuoka

British Journal of Cancer

8

0 references

language of work or name

English

0 references

publication date

18 September 2006

0 references

published in

0 references

volume

95

0 references

issue

6

0 references

page(s)

677-82

0 references

cites work

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360511

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360511

Pemetrexed safety and dosing strategy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360511

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360511

Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360511

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360511

A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360511

Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360511

The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360511

Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360511

Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients

2 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603321

A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate

21 January 2018

1 reference

12 December 2020

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation

1 reference

12 December 2020

Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid

1 reference

12 December 2020

The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603321

1 reference

Dimensions Publication ID

1040932807

0 references

1 reference

1 reference

PubMed publication ID

16940981

1 reference